Cristine Allmer

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

Edgardo R. Parrilla Castellar, Elaine S. Jaffe, Jonathan Said et al. · Blood · 2014 · 466 citations · Full text

Medicine, Oncology, Pathology +16

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

Philip A. Philip, Michelle R. Mahoney, Cristine Allmer et al. · Journal of Clinical Oncology · 2005 · 459 citations · Full text

Medicine, Oncology, Pharmacology +15

Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer

Leonard L. Gunderson, Daniel J. Sargent, Joel E. Tepper et al. · Journal of Clinical Oncology · 2004 · 436 citations · Full text

Medicine, Oncology, Surgery +17

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais et al. · Journal of Clinical Oncology · 2014 · 410 citations · Full text

Medicine, Hematology, Oncology +17

Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer

Philip A. Philip, Michelle R. Mahoney, Cristine Allmer et al. · Journal of Clinical Oncology · 2006 · 317 citations

Medicine, Oncology, Pharmacology +14